Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

ABSTRACT: The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

DISEASE(S): Patients Undergoing Curative Surgery For Colorectal Cancer,Colorectal Cancer Stage Iv,Colorectal Cancer Recurrent,Colorectal Neoplasms,Colorectal Cancer Metastatic,Cancer,Colorectal Cancer Stage Iii

PROVIDER: 2283240 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

SGM-101 in Colorectal Brain Metastases.

Project description:This study assesses the feasibility of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen monoclonal antibody, for intraoperative near-infrared fluorescence imaging of colorectal brain metastases by injecting SGM-101 intravenously 3 - 5 days prior to surgery.

| 2367476 | ecrin-mdr-crc

Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas

Project description:This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery. SGM-101 is injected 2 to 4 days before surgery and visualized using an optimized camera system.

| 2230594 | ecrin-mdr-crc

Fluorescence guidance surgery with SGM-101 patients with colorectal lung metastasis

Project description:Primary objectives: 1. To determine the feasibility of SGM-101 for intraoperative imaging of colorectal lung metastases - Concordance between fluorescent signal and tumor status of resected tissue Primary endpoints: Concordance between intraoperative fluorescence assessment of resected lesions and their histopathology in terms of both CEA expression and tumor status.

| 2539239 | ecrin-mdr-crc

SGM-101 in Colorectal Lung Metastases

Project description:Near-infrared fluorescence-guided oncologic surgery (FGOS) with the use of a tumor specific tracer (SGM-101) developed by Surgimab can provide valuable intra-operative information about tumor location and extensiveness. SGM-101 already proven to be safe and valuable in colorectal cancer. This study aims to prove feasibility for colorectal lung metastases.

| 2366037 | ecrin-mdr-crc

Streptococcus macedonicus strain:SGM CIP105683T

Project description:Streptococcus gallolyticus subsp. macedonicus (SGM CIP105683T) Genome sequencing

| PRJNA940176 | ENA

SGM-101 in Colorectal Lung Metastasis (SGMCLM)

Project description:Primary outcome(s): -Concordance between intraoperative fluorescence assessment of resected lesions and their histopathologic result Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Other

| 2442287 | ecrin-mdr-crc

Intraoperative molecular imaging of colorectal lung metastases with SGM-101: a feasibility study.

Project description:PurposeMetastasectomy is a common treatment option for patients with colorectal lung metastases (CLM). Challenges exist with margin assessment and identification of small nodules, especially during minimally invasive surgery. Intraoperative fluorescence imaging has the potential to overcome these challenges. The aim of this study was to assess feasibility of targeting CLM with the carcinoembryonic antigen (CEA) specific fluorescent tracer SGM-101.MethodsThis was a prospective, open-label feasibility study. The primary outcome was the number of CLM that showed a true positive fluorescence signal with SGM-101. Fluorescence positive signal was defined as a signal-to-background ratio (SBR) ≥ 1.5. A secondary endpoint was the CEA expression in the colorectal lung metastases, assessed with the immunohistochemistry, and scored by the total immunostaining score.ResultsThirteen patients were included in this study. Positive fluorescence signal with in vivo, back table, and closed-field bread loaf imaging was observed in 31%, 45%, and 94% of the tumors respectively. Median SBRs for the three imaging modalities were 1.00 (IQR: 1.00-1.53), 1.45 (IQR: 1.00-1.89), and 4.81 (IQR: 2.70-7.41). All tumor lesions had a maximum total immunostaining score for CEA expression of 12/12.ConclusionThis study demonstrated the potential of fluorescence imaging of CLM with SGM-101. CEA expression was observed in all tumors, and closed-field imaging showed excellent CEA specific targeting of the tracer to the tumor nodules. The full potential of SGM-101 for in vivo detection of the tracer can be achieved with improved minimal invasive imaging systems and optimal patient selection.Trial registrationThe study was registered in ClinicalTrial.gov under identifier NCT04737213 at February 2021.

| S-EPMC11300526 | biostudies-literature

ChIP-seq BHT-101 cells and BHT-101 ASH1L KO cell lines

Project description:The goal of this study is to assess the role of ASH1 like histone lysine methyltransferase (ASH1L) in the biology of anaplastic thyroid cancer. CRISPR-Cas9 was used to create cell lines derived from BHT-101 anaplastic thyroid cancer cells with premature stop codons prior to the catalytic domain within both alleles of ASH1L. ChIP-seq for H3K36me2, the histone mark catalyzed by ASH1L, was performed on two KO cell lines, and compared to wild type BHT-101 cells.

2020-05-09 | GSE147074 | GEO

RNA-seq BHT-101 cells and BHT-101 ASH1L KO cell lines

Project description:The goal of this study is to assess the role of ASH1 like histone lysine methyltransferase (ASH1L) in the biology of anaplastic thyroid cancer. CRISPR-Cas9 was used to create 4 independent cell lines derived from BHT-101 anaplastic thyroid cancer cells with premature stop codons prior to the catalytic domain within both alleles of ASH1L. RNA-seq was performed on these 4 KO cell lines, and compared to 3 biological replicates of wild type BHT-101 cells.

2020-05-09 | GSE147076 | GEO

microRNA-101 represses EZH2 in cancer

Project description:To determine the phenotypic overlap between restoring miR-101 expression in bladder cancer cells and knocking down EZH2. Either control precursors, pre-miR-101, control siRNA, or EZH2 siRNA were transfected in triplicate into UM-UC-3 cells for 72 hours at a final concentration of 50 nM.

2010-06-25 | E-GEOD-13674 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data